Deciding to adopt a biosimilar?
By understanding the totality of evidence, and the potential long-term
savings the biosimilar may provide to the health care system, the
payer landscape, and the stakeholders involved, you will be prepared
to build a consensus in your organization.
Building knowledge
Collecting information needed by all stakeholders involved in the decision to adopt a biosimilar
Who should be involved?
Assessing the payer landscape
Consulting with internal experts to get an initial understanding of the payer landscape
Who should be consulted?
Building A Consensus
Bring together the right internal colleagues
Who should work together to reach a consensus?
Implementing a biosimilar
In Phase 2, the nuts and bolts of implementing a biosimilar come to
the surface. You’ll learn about the necessity of updating systems, how to address the payer
landscape and the reimbursement process, and preparing the appropriate educational and
communication materials for health care professionals and patients.
Updating Systems
Preparing for the digital transition
Who should be involved?
Addressing payer landscape and reimbursement
Understanding the administrative and regulatory details
Who should play a role?
Educating and communicating key information
Putting patients and process first in your preparations
Who should be involved in these communications?
Going live
Ensuring the readiness of your institution
Who should understand the changes?
Monitoring biosimilar use and experience
Phase 3 will cover the importance of establishing a system to measure
the success of biosimilar implementation. Essential assessments
include evaluating the quality of the experience for health care
professionals and patients, the utilization of the biosimilar, and the
impact of biosimilar adoption on the organization as a whole.
Measuring and proving success
Using data to evaluate outcomes and track the progress of your goals
Who should help establish the Key Performance Indicators?
Possible reporting data
Maintaining metrics for accountability and quickly identifying improvement opportunities
Who should evaluate the data?
Learn more about biosimilars for your institution
Advocating for Biosimilars
Interactive educational resource for pharmacists exploring the potential value biosimilars may bring to the health care system.
Confidence in Biosimilars
Interactive educational resource for pharmacists providing an overview of clinical considerations for biosimilars.
Championing Biosimilars
Interactive educational resource discussing the role health system pharmacists play in the successful implementation of biosimilars.
Need more information on biosimilars? We’re here.
Organon does not guarantee that your use of this information will help you achieve your biosimilars goals. This educational resource was prepared in consultation with, and with the permission of, a health care administrator at a major health care institution who had successfully implemented a biosimilars switch within their organization. The adoption process and roles may vary by institution.
Decide
Implement
Monitor